Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2024 Product Revenue and Provides Business Update Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year January 13, 2025, CONCORD, Calif.—(BUSINESS WIRE)—Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdic ...

Cerus Corporation (NASDAQ:CERS) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Matthew Park - Cantor Fitzgerald Colin Wells - Stifel Jacob Johnson - Stephens Joshua Jennings - TD Cowan Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the C ...

Cerus (CERS) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this biomedical products company would post a loss of $0.04 per share when it actually produced a loss of $0.03, delivering a surprise of 25%.Over the last four quarters, the company has s ...

Exhibit 99.1 Cerus Corporation Announces Third Quarter 2024 Financial Results Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million CONCORD, CA, October 30, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial results for its third quarter and nine months ended ...

Cerus Corporation (NASDAQ:CERS) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Jessica Hanover - VP, Corporate Affairs Obi Greenman - President & CEO Vivek Jayaraman - COO Kevin Green - CFO Conference Call Participants Ross Osborne - Cantor Fitzgerald Jacob Johnson - Stephens Eric Anderson - TD Cowen Vidyun Bais - BTIG William Bonello - Craig-Hallum Capital Group Operator Good day, ladies and gentlemen. Thank you for standing by, and welcome to the Cerus Corporation Second Q ...

Cerus (CERS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 25%. A quarter ago, it was expected that this biomedical products company would post a loss of $0.04 per share when it actually produced a loss of $0.05, delivering a surprise of -25%. Over the last four quarters, the company has s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number 000-21937 CERUS CORPORATION (Exact name of registrant as specified in its charter) Delaware 68-0262011 (State or other jurisdiction ...

Exhibit 99.1 Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million CONCORD, CA, August 1, 2024 - Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months end ...

Cerus Corporation (NASDAQ:CERS) Q1 2024 Results Conference Call May 2, 2024 4:30 PM ET Company Participants Jessica Hanover - Vice President of Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green - Chief Financial Officer Carol Moore - Senior Vice President of Regulatory and Quality Conference Call Participants Emily Christy - Stifel Jacob Johnson - Stephens Ross Osborne - Cantor Fitzgerald William Bonello - Craig-Hallum Capital Group ...